Drug
Alcaftadine clinical trials
Also written Lastacaft.
- studies test it
- 10
- open now
- 0
- in phase 3
- 5
- first study started
- 2005
How studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2005 (3)
| Year | Studies |
|---|---|
| 2005 | 3 |
| 2006 | 1 |
| 2009 | 1 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 3
- 5
- Phase 4
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 1
Vistakon Pharmaceuticals (5) · Allergan (2) · ORA, Inc. (1) · Starx Research Center, LLC (1) · Hom, Milton M., OD, FAAO (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses alcaftadine is read from its arms, and is right about nine times in ten.
Testing it · 10
- A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft as Measured by In-Vivo Confocal MicroscopyCompletedPhase 4ORA, Inc.NCT02308501Written as Lastacaft ®
- Safety and Efficacy Study of a Eye Drop for Eye AllergyCompletedPhase 3Vistakon PharmaceuticalsNCT00889330Written as alcaftadine
- Safety Study of Ophthalmic Solution in Healthy, Normal VolunteersCompletedPhase 3Vistakon PharmaceuticalsNCT00223951Written as R89674 (generic name not yet established)
- A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic ConjunctivitisCompletedPhase 4AllerganNCT01732757Written as Alcaftadine 0.25%
- Ocular Allergy Treatment Practical Impact TrialStatus unknownPhase 4Starx Research Center, LLCNCT01808768Written as Alcaftadine
- A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic ConjunctivitisCompletedPhase 4AllerganNCT01470118Written as alcaftadine 0.25% ophthalmic solution
- Evaluation of Efficacy of Ophthalmic Solution in Seasonal Allergic ConjunctivitisCompletedPhase 3Vistakon PharmaceuticalsNCT00364091Written as R89674 0.025% ophthalmic solution
- Evaluation of Efficacy of Ophthalmic Solution in Induced Acute Allergic ConjunctivitisCompletedPhase 3Vistakon PharmaceuticalsNCT00241319Written as R89674 (generic name not yet established)
- Evaluation of Efficacy of Ophthalmic Solution in Induced Allergic ConjunctivitisCompletedPhase 3Vistakon PharmaceuticalsNCT00244543Written as R89674 (generic name not yet established)
- Comparison of Tolerability Between Two Allergy DropsStatus unknownPhase 4Hom, Milton M., OD, FAAONCT01390961Written as alacaftadine and naphazoline HCl & pheniramine maleate
Codes
What other systems call alcaftadine · ClinicalTrials.gg INT005817
- MeSH (NLM) C557708alcaftadineConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 7Z8O94ECSXALCAFTADINEConfirmed FDA, NLM, Wikidata
- RxNorm 1000082Confirmed FDA, Wikidata
- Wikidata Q4712900alcaftadineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C72686AlcaftadineOne source FDA
- DrugBank DB06766One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C557708 | alcaftadine | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 7Z8O94ECSX | ALCAFTADINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1000082 | — | Confirmed FDA, Wikidata |
| Wikidata | Q4712900 | alcaftadine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C72686 | Alcaftadine | One source FDA |
| DrugBank | DB06766 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.